Inpatient Treatment of Suicidality: A Systematic Review of Clinical Trials.
Ali Abdolizadeh, Brett D M Jones, Maryam Hosseini Kupaei, Amal Shah, Terri Rodak, Salman Farooqui, Mohammed Omair Husain, Cory R Weissman, Juveria Zaheer, David Gratzer, Daniel M Blumberger, Muhammad Ishrat Husain
The Journal of clinical psychiatry January 8, 2025 DOI: 10.4088/JCP.24r15382 via PubMed
Summary
AI-generated from the abstractA systematic review of treatments for suicidality among psychiatric inpatients aged 18–65 found that intravenous ketamine produced the most consistent rapid reduction in suicidality among 14 pharmacologic trials. Among 35 nonpharmacologic trials—including chronotherapy, neurostimulation, and psychotherapies—results were mixed, with some interventions showing potential benefit, especially for mood, personality, and trauma-related disorders. Many studies had methodological limitations such as nonrandomized designs and lack of control groups. The review calls for larger, well-designed trials to confirm effectiveness.
Study at a glance
| Characteristics | Systematic review Randomized Qualitative Peer reviewed |
|---|---|
| Population | Psychiatric inpatients aged 18-65 with moderate to high levels of suicidality |
| Interventions | intravenous ketamine chronotherapy neurostimulation psychotherapies |
| Keywords | Ketamine therapy Suicide prevention Psychiatric treatment Mental health interventions Clinical trials |
| Citations | 2 |
| Key finding | Intravenous ketamine showed the most consistent rapid reduction in suicidality among pharmacologic interventions, while nonpharmacologic treatments had mixed results. |
Abstract
Objective: Psychiatric inpatients represent an acutely vulnerable population with high rates of suicidality (ie, suicidal ideation, attempts, and completed suicide). This systematic review aimed to evaluate treatments for suicidality delivered within inpatient settings. Data Sources: MEDLINE, Embase, APA PsycInfo, CINAHL, and The Cochrane Library were systematically searched using 3 concepts: suicidality, inpatient population/setting, and treatment/ interventions. Searches were limited to years 2001-2024, with no language restrictions. Study Selection: Of 19,921 articles identified, 11,519 were screened, and 179 underwent full-text review. We included clinical trials on pharmacologic and nonpharmacologic interventions for suicidality in psychiatric inpatients aged 18-65 with moderate to high levels of suicidality that measured changes in suicidality. Data Extraction and Synthesis: Studies were organized into tables by study design, treatments, participants, suicide measure, outcomes, and key findings. Due to heterogeneity, a meta-analysis was not conducted; instead, a narrative synthesis was used for qualitative analysis. Results: Forty-nine studies were included. Of 14 pharmacologic trials, intravenous ketamine showed most consistent rapid reduction in suicidality. Thirty-five nonpharmacologic trials, covering a broad spectrum of treatments including chronotherapy, neurostimulations, and psychotherapies, were reviewed. The results were mixed, with some interventions showing potential in reducing suicidality, particularly in the mood, personality, and trauma-related disorders. Many studies had methodological concerns including nonrandomized designs, lack of control arms, and retrospective assessments. Conclusion: A range of interventions for treating suicidality in inpatient settings have been evaluated, with mixed results. The current review underscores the need for larger, well-designed trials to assess the effectiveness of these treatments in inpatient settings.